“…At levels above 19 normal physiological concentrations, FFAs can induce morphological 20 changes in erythrocytes both in vitro and in vivo (Kamada et al,1987;21 Söderberg et al, 2009), and several diseases are associated with 22 elevated concentrations of FFAs (Dhainaut et al, 1987;Lefevre et al, 23 1988; Roden et al, 1996;Egan et al, 1999;Kurien and Oliver, 1966;24 Oliver, 1972;Mozaffarian et al, 2006). 25 In a previous study, injectable anesthetic depot formulations 26 (lidocaine-prilocaine 1:1) were tested on rats to induce ultra-long 27 nerve blockades by administration directly next to the sciatic nerve 28 (Söderberg et al, 2006). Below a concentration of 20% active Abbreviations: C, concentration; EC50 in vitro , concentration required to obtain 50% of the maximal attainable effect in terms of measured interfacial pressure in vitro; n H , Hill coefficient; P, interfacial pressure; P max , maximal attainable interfacial pressure; P rel , relative interfacial pressure; g 0 , interfacial tension of the pure fluid/solution (reference system); g, interfacial tension of the pure fluid/ solution including the active substance; C 2:0 , acetic acid; C 6:0 , caproic acid; C 8:0 , caprylic acid; C 10:0 , capric acid; C 12:0 , lauric acid; C 16:0 , palmitic acid; AP, ampicillin; BP, benzylpenicillin; CE, cefuroxime; CX, cloxacillin; DC, dicloxacillin; ER, erythromycin; EDTA, edetate dipotassium; FFAs, free fatty acids; HSA, human albumin; PBS, phosphate-buffered saline solution; EaHy926, endothelial hybrid cell line; HUVEC, human umbilical vein endothelial cell; ICAM, intercellular adhesion molecule.…”